Review
Pharmacology & Pharmacy
Xuan He, Yubing Li, Xinyu Deng, Xiaolin Xiao, Jinhao Zeng
Summary: The current meta-analysis could not consistently verify the efficacy of resveratrol in treating nonalcoholic fatty liver disease, but demonstrated its liver-protective effects. Further large-sample scale and single region randomized controlled trials are needed to investigate its efficacy.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Claudia Vales-Villamarin, Olaya de Dios, Iris Perez-Nadador, Teresa Gavela-Perez, Leandro Soriano-Guillen, Carmen Garces
Summary: The study found that the Ala12Ala genotype was significantly more common in obese females, with carriers having higher weight and BMI. In males, the Ala12Ala genotype was associated with significantly higher levels of HDL-cholesterol and apoA-I. In females, carriers of Ala12Ala seemed to have higher levels of leptin.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Endocrinology & Metabolism
Yong-Tian Zheng, Tian-Mei Xiao, Chan-Xian Wu, Jin-Yan Cheng, Le-Yu Li
Summary: The study identified that the polymorphisms rs266729 and rs3774261 in the adiponectin gene may be risk factors for NAFLD and remained significantly associated in different samples, holding potential for novel therapeutic strategies. However, these findings still need to be validated in larger, well-designed studies.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Medicine, General & Internal
Bing-Feng Chen, Yeuh Chien, Pin-Hsing Tsai, Pang-Chung Perng, Yi-Ping Yang, Kuan-Chun Hsueh, Chia-Hung Liu, Yuan-Hung Wang
Summary: The study found that the APOC3 gene -455T/C polymorphism may be associated with NAFLD risk in non-Asian populations, but not in Asian populations; while the -482C/T polymorphism showed no significant association with NAFLD risk. Additional studies with other functional polymorphisms are needed to further explore the effects of the APOC3 gene on NAFLD.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
(2021)
Article
Nutrition & Dietetics
Danijela Ristic-Medic, Marijana Kovacic, Marija Takic, Aleksandra Arsic, Snjezana Petrovic, Marija Paunovic, Maja Jovicic, Vesna Vucic
Summary: This study evaluated the effects of calorie-restricted Mediterranean and low-fat diets on patients with NAFLD. Both diets resulted in significant weight loss and improvements in liver status and cardiometabolic markers. The Mediterranean diet may have additional benefits compared to the low-fat diet by improving fatty acid profiles and FLI in NAFLD patients.
Review
Surgery
Guang-Peng Zhou, Yi-Zhou Jiang, Li-Ying Sun, Zhi-Jun Zhu
Summary: This study found no difference in posttransplant survival between NASH and non-NASH patients. Carefully selected NASH patients with hepatocellular carcinoma (HCC) may benefit from liver transplantation. NASH recipients should be managed with caution posttransplant, especially regarding the potentially high risk of sepsis-related death.
INTERNATIONAL JOURNAL OF SURGERY
(2022)
Article
Endocrinology & Metabolism
Rong Xie, Shaobo Tang, Yanna Yang
Summary: The meta-analysis revealed that there is no association between the PPAR-gamma Pro12Ala polymorphism and NAFLD, both in Asian and Caucasian populations.
JOURNAL OF DIABETES AND ITS COMPLICATIONS
(2022)
Review
Gastroenterology & Hepatology
Jie Ning Yong, Wen Hui Lim, Cheng Han Ng, Darren Jun Hao Tan, Jieling Xiao, Phoebe Wen Lin Tay, Snow Yunni Lin, Nicholas Syn, Nicholas Chew, Benjamin Nah, Yock Young Dan, Daniel Q. Huang, Eunice Xiang Xuan Tan, Arun J. Sanyal, Mazen Noureddin, Mohammad Shadab Siddiqui, Mark D. Muthiah
Summary: This study conducted a time-dependent survival analysis comparing the survival of liver transplant recipients with and without nonalcoholic steatohepatitis (NASH). The overall survival was comparable between NASH and non-NASH patients after liver transplantation. However, NASH patients with higher model for end-stage liver disease scores had worse overall survival.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Review
Clinical Neurology
Yunpeng Gu, Wei Zhang, Yanli Hu, Yutong Chen, Junping Shi
Summary: Nonalcoholic fatty liver disease (NAFLD) is significantly associated with depression, and individuals with NAFLD have an increased risk of depression. Additionally, depressed patients have a higher risk of developing NAFLD compared to non-depressed patients.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Review
Medicine, General & Internal
Xiangyu Zhou, Jincheng Wang, Sufang Zhou, Jiajia Liao, Zuoyu Ye, Leiming Mao
Summary: This meta-analysis systematically evaluated the efficacy and safety of probiotics in the treatment of nonalcoholic fatty liver disease (NAFLD) through published randomized controlled trials. The results showed that probiotic intervention significantly reduced liver function, blood lipid level, blood glucose levels, and insulin levels, effectively improving hepatic steatosis in NAFLD patients. However, no significant improvements were observed in BMI, inflammatory factors, or insulin resistance.
Review
Nutrition & Dietetics
Ling Pan, Jing Sui, Ying Xu, Qun Zhao
Summary: This meta-analysis examines the relationship between nut consumption and the risk of NAFLD. The results indicate a significant negative correlation between nut intake and NAFLD, particularly in females.
Review
Gastroenterology & Hepatology
Lorenzo A. Orci, Marco Sanduzzi-Zamparelli, Berta Caballol, Victor Sapena, Nicola Colucci, Ferran Torres, Jordi Bruix, Maria Reig, Christian Toso
Summary: Nonalcoholic fatty liver disease (NAFLD) may be a risk factor for hepatocellular carcinoma (HCC), and this study used meta-analysis to analyze the incidence rates of HCC in NAFLD patients. The results showed that NAFLD patients with cirrhosis have a similar risk of developing HCC compared to cirrhosis patients with other causes. However, the incidence of HCC in nonalcoholic steatohepatitis or simple steatosis patients is lower.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Medicine, General & Internal
Yi Zhu, Jian-Hua Yang, Jun-Ping Hu, Ming Qiao
Summary: This study revealed that the GSTM1 null, GSTT1 null and GSTP1-Val genotypes might be related to increased NAFLD susceptibility.
Review
Endocrinology & Metabolism
Nader Salari, Niloufar Darvishi, Kamran Mansouri, Hooman Ghasemi, Melika Hosseinian-Far, Fateme Darvishi, Masoud Mohammadi
Summary: This meta-analysis suggests that individuals with CC genotype have a 52% lower chance of developing non-alcoholic fatty liver disease, while those with CG genotype have a 19% higher risk and those with GG genotype have a 105% higher risk. Furthermore, individuals with CG + GG genotypes combined are 88% more likely to have NAFLD.
BMC ENDOCRINE DISORDERS
(2021)
Article
Gastroenterology & Hepatology
Rui-Nan Zhang, Feng Shen, Qin Pan, Hai-Xia Cao, Guang-Yu Chen, Jian-Gao Fan
Summary: The study confirmed the association between PPARGC1A rs8192678 and NAFLD, and found that the risk A allele was related to more severe steatosis, higher activity, and NASH in NAFLD patients, independently of PNPLA3 rs738409.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)